People · Operator
Named in public records as an officer, director or promoter · active 2013–2015 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| KALA BIO, Inc. | — | Biotechnology | Series C | $158.8M | $8.3M | 2013 |
| Gensight Biologics S.A. | — | Biotechnology | Series B | $25.0M | $991.7M | 2015 |
Bernard Gilly at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Bernard Gilly on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 1 | 36 |
| Kevin Bitterman | 1 | 15 |
| Robert Tepper | 1 | 7 |
| DAVID LAZAR | 1 | 5 |
| Florent Gros | 1 | 4 |
| PETER COUROSSI | 1 | 4 |
| Andrew I. Koven | 1 | 4 |
| Eric L. Trachtenberg | 1 | 4 |
| ROBERT PAULL | 1 | 4 |
| Brendan Purdy | 1 | 4 |
| Mark Iwicki | 1 | 4 |
| Andrea Franz | 1 | 4 |
| Howard B. Rosen | 1 | 4 |
| JUSTIN HANES | 1 | 3 |
| Greg Grunberg | 1 | 3 |
| Gregory D. Perry | 1 | 3 |
| Guido Magni | 1 | 3 |
| Karen Wagner | 1 | 2 |
| Andrew L. Koven | 1 | 2 |
| C. Daniel Myers | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.